i-ROK Foundation   Report issue

Foundation Phase 2
Founded: Excelsior Springs MO United States (2009)
Status: No NME R&D (2009)

Organization Overview

First Clinical Trial
2019
NCT04129151
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

i-ROK Foundation

Active Ingredients

Drugs in Phase 2 Trials (2)

ganitumab (1 trial)

palbociclib (ibrance) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2